Product REF 4000-100N, DRAIN, EXPRESS SINGLE W/AC, Single Collection
FDA Device Recall #Z-0709-2024 - Class I, December 13, 2023
Recall Summary
| Recall Number | Z-0709-2024 |
| Classification | Class I - Serious risk |
| Date Initiated | December 13, 2023 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Maquet Cardiovascular, LLC |
| Location | Wayne, NJ |
| Product Type | Devices |
| Quantity | (34,356 cases/206,136 devices US); (3,902 cases/23,412 devices OUS) |
Product Description
Product REF 4000-100N, DRAIN, EXPRESS SINGLE W/AC, Single Collection
Reason for Recall
Express chest drains are pre-packaged with sterile water syringes which have bene recalled. If the device is not kept in an upright position, the patient may be exposed to infectious material. Subsequent hazards include but are not limited to infection, abscess, sepsis, and death.
Distribution Pattern
Worldwide distribution: US (nationwide) and OUS (Foreign) to countries of: Australia, Brazil, Canada, Luxembourg, Netherlands, Norway, Spain and UK
Lot / Code Information
UDI-DI 00650862115130 Lots 499822 490138 499344 498578 499805 498974 498063 497139 495208 496692 487810 489877 489878 496208 496207 496774 495194 495193 494224 493679 492644 492079 490762 490744 487809 489161 485228 483533 487808 485231 486071 485230 483108 485229 483534 475228 475487 483107 483180 477950 474982 474076 474511 472581 473747 474950 474077 474967 469918 469920 471069 471805 471806 469403 470148 468857 469402 469919 467195 468858 468395 468856 467476 467475 466637 466951 467193 467194 466455 467352 466267 466080
Other Recalls from Maquet Cardiovascular, LLC
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-2741-2026 | Class II | The Vasoview Hemopro 2 Endoscopic Vessel Harves... | Jun 2, 2026 |
| Z-2586-2025 | Class II | Heartstring III Proximal Seal System. Intravas... | Aug 15, 2025 |
| Z-2588-2025 | Class II | Heartstring III Proximal Seal System, 4.3 MM. I... | Aug 15, 2025 |
| Z-2587-2025 | Class II | Heartstring III Proximal Seal System, 3.8 MM. I... | Aug 15, 2025 |
| Z-2636-2025 | Class II | Vasoview Hemopro 3 Endoscopic Vessel Harvesting... | Aug 6, 2025 |
Frequently Asked Questions
Sterility recalls for medical devices vary in severity. If you have already had a procedure using a potentially non-sterile device, contact your healthcare provider immediately, you may need monitoring for signs of infection. Symptoms to watch for include fever, redness or swelling at the surgical site, unusual pain, or discharge. For devices that have not yet been used, they should be quarantined and returned to the manufacturer per the recall notice. Non-sterile implants can cause serious infections; early detection and treatment are critical.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency, Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.